CSI Market
Sign In | Register

Jasper Therapeutics Inc (JSPR) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access JSPR Annual Cash Flow →
This page allows investors to follow Jasper Therapeutics Inc's cash flow patterns across multiple reporting periods and assess consistency in cash generation.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-3.93
Depreciation & amortization42.04
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.90
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.08
Share-based Compensation1.19
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants-13.62
Interest Earned On Marketable Securities Held In Trust Account-
Change In Value Of Common Stock Subject To Possible Redemption-
Operating Lease Right Of Use Asset Amortization Expense-
Liabilities Fair Value Adjustment-
Increase Decrease In Operating Lease Liability-0.48
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Receivables0.00
Increase (Decrease) in Accounts Payable-3.44
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities-0.95
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-2.11
Other Working Capital-0.07
Other Noncash Expense0.37
Other net0.00
Payments for (Proceeds from) Other Operating Activities-41.92
Discontinued operations0.00
Net Cash flow from Operating Activities-21.47
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.08
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Cash Withdrawn From Trust Account To Pay For Franchise Taxes-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.08
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.01
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Sale Of Units Net Of Underwriting Discounts Paid-
Net Proceeds From Reverse Recapitalization And P I P E Financing Net Of Assets And Liabilities Ass-
Conversion Of Redeemable Convertible Preferred Stock Into Common Stock In Connection With Reve-
Deferred Issuance Costs Reclassified To Additional Paid In Capital-
Net Liabilities Assumed Upon The Closing Of Reversed Recapitalization-
Recognition Of Earnout Liability-
Recognitionsettlement Of Derivative Tranche Liability-
Payments Of Offering Costs-
Payment Of Reverse Recapitalization Related Expenses-
Proceeds From Issuance Of Common Stock Through A T M And Underwriting Offerings Net-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents29.11
Unpaid Offerings Issuance Costs Included In Accounts Payable And Accrued Expenses-
Vesting Of Founders Restricted Stock-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.01
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-21.39
Total Cash Flow-21.38
4 historic quarters locked

Sign in to unlock the full Jasper Therapeutics Inc cash flow history.

Sign In Create Free Account

About Jasper Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001213900-26-089592

Figures are derived from filed reports and may be restated. Historical data is subject to revision.